Abstract: A therapeutic method is provided, employing an antiviral compound of the general formula: ##STR1## wherein Z is H, OR' or N(R).sub.2, wherein R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R).sub.2, SR, OR' or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to a dissipating device that uses a high-efficiency radiator for natural convection heat dissipation for a CPU (central processing unit) or an IC (integrated circuit) die with low cost. The radiator is formed by screen plates punched to form many tilted rhombus cells constructed by many wave-shaped mesh wires having a flat rectangular cross-section. The screen plates are made of good heat-conductive metal material. A plurality of the screen plates are overlapped in various orientations so that the heat dissipating effect can be improved, radiating heat through natural convection.

Abstract: A solar battery which has thin film type of single crystal silicon, and a method for manufacturing such a solar battery is disclosed. A transparent glass plate is adhered to an upper surface of a silicon substrate, having active regions to transform solar energy into electric energy. The bottom surface of the substrate is ground from hundreds of micrometers to several tens of micrometers, or even to several micrometers in thickness such that the substrate is semi-transparent or transparent. An anti-reflective layer is coated over the bottom surface of the substrate so as to increase the possibility for the incident light onto the solar battery to convert into electric energy and further improve the efficiency of energy transformation.

Abstract: A therapeutic method is provided, employing an antiviral compound of the general formula: ##STR1## wherein Z is H, OR' or N(R).sub.2, where n R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P (OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R).sub.2, SR, OR' or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: A method is provided for preparing an antiviral compound of formula (I): ##STR1## wherein Y is CH, Z is H or NH.sub.2, and X is halo, comprising: (a) reacting a compound of formula (II): ##STR2## with triethylorthoformate, and (b) hydrolyzing the product of said reaction in the presence of acid to yield said compound of formula (I).

Abstract: A therapeutic method is provided, employing an antiviral compound of the general formula: ##STR1## wherein Z is H, OR' or N(R).sub.2, wherein R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R).sub.2, SR, OR' or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: A therapeutic method is provided, employing an antiviral compound of the general formula: ##STR1## wherein Z is H, OR' or N(R).sub.2, wherein R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R).sub.2, SR, OR' or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: A therapeutic method is provided, employing an antiviral compound of the general formula: ##STR1## wherein Z is H, OR' or N(R) .sub.2, wherein R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH) .sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R) .sub.2, SR, OR' or halogen, wherein R is H, lower (C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: Antiviral and antitumor compounds are disclosed of general formula: ##STR1## wherein Z is H, OR' or NH.sub.2, wherein R' is H, (C.sub.1 -C.sub.4)-alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R.sub.2), SR, OR' or halogen, wherein R is H, lower-(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically-acceptable salts thereof.

Abstract: Antiviral and antitumor compounds are disclosed of general formula: ##STR1## wherein Z is H, OR' or NH.sub.2, wherein R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R.sub.2), SR, OR' or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically-acceptable salts thereof.

Abstract: Antiviral and antitumor compounds are disclosed of general formula: ##STR1## wherein Z is H, OH or NH.sub.2, Y is CH or N, the bond indicated by C.sub.1 '--C.sub.2 ' is absent or, in combination with the C.sub.1 '--C.sub.2 ' bond is the unit CH.dbd.CH, and X is selected from the group consisting of H, N(R.sub.2), SR, OR or halogen, wherein R is H, lower (C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.